WBDE: The first subject has been enrolled in the Phase II/III clinical trial of Shishanjianjia controlled-release tablets

WBDE announced that its wholly-owned subsidiary, WBDE Pharmaceutical Group Co., Ltd., has completed the enrollment of the first subject in the Phase II/III pivotal registration clinical trial of the Class 2 new drug Huperzine A controlled-release tablets for the treatment of mild to moderate Alzheimer's disease dementia. Huperzine A controlled-release tablets utilize a biphasic controlled-release technology to smooth the drug release peak and trough curve, extending the drug release time in the body, thereby achieving rapid onset, reducing adverse reactions, and enhancing the dosage with good safety. At the same time, the controlled-release technology supports once-daily dosing, improving patient convenience and long-term adherence. This clinical trial will comprehensively validate the overall clinical value and benefits of Huperzine A controlled-release tablets, providing new options for Alzheimer's disease treatment